VOICE study will continue as it considers what action to take after results of two trials

Researchers from two major HIV prevention trials have announced favorable results of an approach called pre-exposure prophylaxis (PrEP), which involves the use of drugs commonly used for treating HIV. One of these, the Partners PrEP study, provides the strongest evidence yet of PrEP's effectiveness. A full evaluation is needed to determine the best course for VOICE, an ongoing study of more than 5,000 women in sub-Saharan Africa testing both PrEP and the vaginal microbicide tenofovir gel.

Read the whole article on Science Daily

More from Science Daily